{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T20:40:35Z","timestamp":1793738435479,"version":"4.6.1"},"reference-count":41,"publisher":"American Chemical Society (ACS)","issue":"23","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01GM140026"],"award-info":[{"award-number":["R01GM140026"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Heidelberg Pharma AG","id":[{"id":"https:\/\/ror.org\/036sabf92","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The advent of immuno-oncology therapeutics has given rise to antibody-drug conjugates (ADC) designed to selectively activate pattern recognition receptors such as Toll-Like Receptors (TLRs). In contrast to classical ADC technology, these Immune Stimulating Antibody Conjugates (ISACs) are widely reported to rely on Fc\u03b3-mediated uptake and noncleavable linkers. Herein, we systematically study the impact of Fc effector function, linker cleavability, and conjugation strategy on the efficacy and immunogenicity of a series of TLR7 agonist-based ISACs. We demonstrate that the combination of Fc\u03b3R-ablation and incorporation of a cleavable linker results in increased stimulation of myeloid cells, enhanced efficacy, and improved tolerability as compared to traditional ISAC designs. Interestingly, we found that all ISAC designs exhibited evidence of antidrug-antibody (ADA) induction. We found that the combination of a cleavable linker, a highly permeable TLR7 agonist payload, and ablation of Fc\u03b3R binding results in ISACs that exhibit particularly favorable properties for continued development.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01908","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:56:50Z","timestamp":1763989010000},"page":"24968-24985","source":"Crossref","is-referenced-by-count":10,"title":["Dissecting\nthe Efficacy and Immunogenicity of TLR7\nAgonist\u2013Antibody Conjugates through the Lens of Fc Effector\nFunction, Conjugation Strategies, and Linker Cleavability"],"prefix":"10.1021","volume":"68","author":[{"given":"Siteng","family":"Fang","sequence":"first","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha R.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Wu","sequence":"additional","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Asikur","family":"Rahman","sequence":"additional","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla K.","family":"Elder","sequence":"additional","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor T.","family":"Ojo","sequence":"additional","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-2437","authenticated-orcid":true,"given":"Tracy A.","family":"Brooks","sequence":"additional","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8890-7018","authenticated-orcid":true,"given":"L. Nathan","family":"Tumey","sequence":"additional","affiliation":[{"name":"Binghamton University , , PO Box 6000, , ,","place":["Binghamton, New York, United States, 13902-6000"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"7","key":"2026072715435073500_cit1","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","article-title":"Cancer Immunotherapy: It\u2019s\nTime to Better Predict Patients\u2019 Response","volume":"125","author":"Pilard","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"3","key":"2026072715435073500_cit2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the Percentage\nof US\nPatients With Cancer Who Are Eligible for Immune Checkpoint Inhibitor\nDrugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Networks Open"},{"key":"2026072715435073500_cit3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21176176","article-title":"Molecular\nSciences Resisting Resistance to Immune Checkpoint Therapy: A Systematic\nReview","volume":"21","author":"Haibe","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"2026072715435073500_cit4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689270","article-title":"Tertiary Lymphoid Structures\nin Cancer: The Double-Edged\nSword Role in Antitumor Immunity and Potential Therapeutic Induction\nStrategies","volume":"12","author":"Kang","year":"2021","journal-title":"Front. Immunol."},{"issue":"17","key":"2026072715435073500_cit5","doi-asserted-by":"publisher","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-18-0729","article-title":"Inhaled TLR9 Agonist Renders Lung Tumors Permissive\nto PD-1 Blockade by Promoting Optimal CD4+ and CD8+ T-Cell Interplay","volume":"78","author":"Gallotta","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"2026072715435073500_cit6","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.jhep.2017.12.008","article-title":"Anti-HBV Response\nto Toll-like Receptor 7 Agonist GS-9620\nIs Associated with Intrahepatic Aggregates of T Cells and B Cells","volume":"68","author":"Li","year":"2018","journal-title":"J. Hepatol."},{"issue":"38","key":"2026072715435073500_cit7","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1039\/c3ob40816g","article-title":"Structure\u2013Activity Relationships\nin Toll-like Receptor 7 Agonistic 1H-Imidazo[4,5-c]Pyridines","volume":"11","author":"Yoo","year":"2013","journal-title":"Org. Biomol. Chem."},{"issue":"4","key":"2026072715435073500_cit8","first-page":"443","article-title":"Melanoma in Situ\nTreated with Topical Imiquimod for Management of Persistently Positive\nMargins: A Review of Treatment Methods","volume":"15","author":"Fan","year":"2015","journal-title":"Ochsner\nJ."},{"issue":"1","key":"2026072715435073500_cit9","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-42784-9","article-title":"Transcriptomic Profiles Conducive\nto Immune-Mediated Tumor Rejection in Human Breast Cancer Skin Metastases\nTreated with Imiquimod","volume":"9","author":"Rozenblit","year":"2019","journal-title":"Sci. Rep."},{"key":"2026072715435073500_cit10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107087","article-title":"Toll-like\nReceptors in Sepsis-Associated Cytokine Storm and Their Endogenous\nNegative Regulators as Future Immunomodulatory Targets","volume":"89","author":"Kumar","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"2026072715435073500_cit11","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1021\/acs.bioconjchem.5b00302","article-title":"Targeted\nActivation\nof Toll-Like Receptors: Conjugation of a Toll-Like Receptor 7 Agonist\nto a Monoclonal Antibody Maintains Antigen Binding and Specificity","volume":"26","author":"Gadd","year":"2015","journal-title":"Bioconjugate Chem."},{"issue":"70","key":"2026072715435073500_cit12","doi-asserted-by":"publisher","first-page":"17721","DOI":"10.1002\/chem.201702942","article-title":"A PH-Sensitive\nMacromolecular Prodrug as TLR7\/8 Targeting Immune Response Modifier","volume":"23","author":"Aichhorn","year":"2017","journal-title":"Chem. - Eur. J."},{"issue":"45","key":"2026072715435073500_cit13","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201803397","article-title":"Nanoparticle-Conjugate TLR7\/8 Agonist\nLocalized Immunotherapy\nProvokes Safe Antitumoral Responses","volume":"30","author":"Nuhn","year":"2018","journal-title":"Adv. Mater."},{"issue":"15","key":"2026072715435073500_cit14","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1021\/acs.biochem.8b00095","article-title":"An Enzyme-Directed\nImidazoquinoline Activated by Drug Resistance","volume":"57","author":"Burt","year":"2018","journal-title":"Biochemistry"},{"issue":"17","key":"2026072715435073500_cit15","doi-asserted-by":"publisher","first-page":"18099","DOI":"10.1021\/acs.jmedchem.5c01500","article-title":"Recent Advances in Peptide Linkers of Antibody\u2013Drug Conjugates","volume":"68","author":"Yang","year":"2025","journal-title":"J. Med. Chem."},{"issue":"1","key":"2026072715435073500_cit16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-Stimulating\nAntibody Conjugates Elicit Robust Myeloid Activation and Durable Antitumor\nImmunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"issue":"12","key":"2026072715435073500_cit17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1158\/2326-6066.CIR-21-0722","article-title":"Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7\nImmune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies","volume":"10","author":"Janku","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"2026072715435073500_cit18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.2538","article-title":"A Phase\n1\/2 Study of a First-in-Human Immune-Stimulating Antibody Conjugate\n(ISAC) BDC-1001 in Patients with Advanced HER2-Expressing Solid Tumors","volume":"41","author":"Li","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"2026072715435073500_cit19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.491","article-title":"209P Interim\nResults of a Phase I\/Ib Study of SBT6050 Monotherapy and Pembrolizumab\nCombination in Patients with Advanced HER2-Expressing or Amplified\nSolid Tumors","volume":"32","author":"Klempner","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"2026072715435073500_cit20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/blood.2024024442","article-title":"Antibody-Drug\nConjugate Adverse Effects Can Be Understood\nand Addressed Based on Immune Complex Clearance Mechanisms","volume":"144","author":"Taylor","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026072715435073500_cit21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms\nof ADC Toxicity and Strategies\nto Increase ADC Tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"2026072715435073500_cit22","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1021\/acs.molpharmaceut.2c00392","article-title":"Design and Characterization of Immune-Stimulating Imidazo[4,5-c]Quinoline\nAntibody-Drug Conjugates","volume":"19","author":"Fang","year":"2022","journal-title":"Mol. Pharmaceutics"},{"key":"2026072715435073500_cit23","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1021\/ACSMEDCHEMLETT.3C00260","article-title":"Synthesis and Optimization\nof 1-Substituted Imidazo[4,5-c]Quinoline TLR7 Agonists","volume":"14","author":"DeYoung","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"2026072715435073500_cit24","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3390\/ph3010146","article-title":"Impact of Glycosylation\non Effector Functions of Therapeutic\nIgG","volume":"3","author":"Abe\u0300s","year":"2010","journal-title":"Pharmaceuticals"},{"issue":"6","key":"2026072715435073500_cit25","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1021\/acs.molpharmaceut.9b00323","article-title":"Thiolation\nof Q295: Site-Specific\nConjugation of Hydrophobic Payloads without the Need for Genetic Engineering","volume":"16","author":"Benjamin","year":"2019","journal-title":"Mol. Pharmaceutics"},{"key":"2026072715435073500_cit26","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1021\/acs.bioconjchem.5c00224","article-title":"Resin-Supported\nSite-Specific Antibody Conjugation Method Leads to Antibody-Drug Conjugates\nwith Retained Efficacy and Improved Stability","volume":"36","author":"Mullapudi","year":"2025","journal-title":"Bioconjugate Chem."},{"key":"2026072715435073500_cit27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2023.129348","article-title":"Generation\nand Structure-Activity Relationships of Novel Imidazo-Thienopyridine\nBased TLR7 Agonists: Application as Payloads for Immunostimulatory\nAntibody Drug-Conjugates","volume":"91","author":"Brant","year":"2023","journal-title":"Bioorg. Med. Chem.\nLett."},{"key":"2026072715435073500_cit28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG Fc Receptors","volume":"19","author":"Ravetch","year":"2001","journal-title":"Annu. Rev.\nImmunol."},{"issue":"5","key":"2026072715435073500_cit29","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/19420862.2017.1323159","article-title":"Affinity of\nHuman IgG Subclasses to Mouse Fc Gamma Receptors","volume":"9","author":"Dekkers","year":"2017","journal-title":"MAbs"},{"issue":"24","key":"2026072715435073500_cit30","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1182\/blood-2012-01-380121","article-title":"Properties\nof Mouse and Human IgG Receptors and Their Contribution to Disease\nModels","volume":"119","author":"Bruhns","year":"2012","journal-title":"Blood"},{"key":"2026072715435073500_cit31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260954","article-title":"Fc-Engineered Antibodies\nwith Immune Effector Functions Completely Abolished","volume":"16","author":"Wilkinson","year":"2021","journal-title":"PLoS One"},{"issue":"48","key":"2026072715435073500_cit32","doi-asserted-by":"publisher","first-page":"44898","DOI":"10.1074\/jbc.M106819200","article-title":"The Human\nLow Affinity Fc\u03b3 Receptors IIa, IIb, and III Bind IgG with Fast\nKinetics and Distinct Thermodynamic Properties","volume":"276","author":"Maenaka","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"20","key":"2026072715435073500_cit33","doi-asserted-by":"publisher","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects\nof Drug Loading on the Antitumor Activity of a Monoclonal Antibody\nDrug Conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"2026072715435073500_cit34","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1021\/acs.molpharmaceut.9b00991","article-title":"An in Vitro Assay Using Cultured\nKupffer Cells Can Predict the Impact of Drug Conjugation on in Vivo\nAntibody Pharmacokinetics","volume":"17","author":"Meyer","year":"2020","journal-title":"Mol. Pharmaceutics"},{"issue":"16","key":"2026072715435073500_cit35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1136\/vr.116.16.431","article-title":"Guidelines on the Recognition of Pain, Distress and\nDiscomfort in Experimental Animals and an Hypothesis for Assessment","volume":"116","author":"Morton","year":"1985","journal-title":"Vet. Rec."},{"key":"2026072715435073500_cit36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117576","article-title":"Advances and Challenges\nin Immunosuppressive Antibody\nDrug Conjugates","volume":"291","author":"Yaseen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"2026072715435073500_cit37","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1039\/D3MD00336A","article-title":"ValCitGlyPro-Dexamethasone Antibody\nConjugates Selectively\nSuppress the Activation of Human Monocytes","volume":"14","author":"Howe","year":"2023","journal-title":"RSC Med. Chem."},{"key":"2026072715435073500_cit38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1021\/acs.bioconjchem.4c00534","article-title":"Targeted Delivery of\nTLR7 Agonists to the Tumor Microenvironment\nEnhances Tumor Immunity via Activation of Tumor-Resident Myeloid Cells","volume":"36","author":"Sega","year":"2025","journal-title":"Bioconjugate Chem."},{"key":"2026072715435073500_cit39","doi-asserted-by":"publisher","first-page":"11322","DOI":"10.1021\/acs.jmedchem.5c00264","article-title":"Discovery and Characterization\nof a First-in-Class LIV1-TLR7\/8 Immunomodulatory Conjugate with Robust\nMyeloid Activation and Antitumor Activity","volume":"68","author":"Yamazoe","year":"2025","journal-title":"J.\nMed. Chem."},{"issue":"5","key":"2026072715435073500_cit40","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1021\/acs.accounts.9b00631","article-title":"Small-Molecule Modulators\nof Toll-like Receptors","volume":"53","author":"Wang","year":"2020","journal-title":"Acc. Chem. Res."},{"issue":"12","key":"2026072715435073500_cit41","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1021\/pr500414q","article-title":"Fc Gamma\nReceptor Glycosylation Modulates the Binding of IgG Glycoforms: A\nRequirement for Stable Antibody Interactions","volume":"13","author":"Hayes","year":"2014","journal-title":"J. Proteome Res."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01908","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/23\/24968\/66288982\/acs.jmedchem.5c01908.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/23\/24968\/66288982\/acs.jmedchem.5c01908.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:56:03Z","timestamp":1785182163000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/23\/24968\/5234485\/Dissecting-the-Efficacy-and-Immunogenicity-of-TLR7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":41,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,11,24]]},"published-print":{"date-parts":[[2025,12,11]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01908","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]}}}